Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(OTCQB:RGBP) Great News -Further Advancement-Treating Cancer-Auto Immune Diseases-Lupus

|Includes: Regen Biopharma, Inc. (RGBP)

www.regenbiopharmainc.com

Great News -Further Advancement

(OTCQB:RGBP) Regen BioPharma, Inc. Sees New-Additional Positive Results for NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases

These compounds are further being refined to increase levels of modulation in the checkpoint. Regen is working towards small molecule therapies that can treat cancer as well as autoimmune disorders such as arthritis and lupus. These compounds have been identified from Regen's patented screening methodology and unique chemical libraries. ChemDiv, Inc. is a fully integrated Target-to-Clinic Contract Research Organization headquartered in San Diego, CA.

Tests on each of these three structures and their analogues have resulted in one particular series becoming the favored activator. Over 250 analogues of this favored structure have been tested and there is a clear relationship between their structure and ability to activate NR2F6.

The NR2F6 nuclear receptor has been identified as a potentially extremely important immune cell inhibitor and cancer stem cell differentiator. Molecules which function as immune cell inhibitors are called 'immune checkpoints' and basically act as an 'on or off switch' to an immune response. Cancer cells sometimes find ways to use these checkpoints to avoid being attacked by the immune system therefore therapies that target these checkpoints demonstrate tremendous potential as cancer treatments.

Read More:

Regen BioPharma, Inc. Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases

PR NewswireMay 16, 2017

https://finance.yahoo.com/news/regen-biopharma-inc-sees-additional-120000036.html

Other Items of Significance:

Regen BioPharma, Inc. Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis

is the only company to be able to advance this far utilizing these compounds. Now that this crucial first phase has been completed, the Company can move forward with ChemDiv on the actual optimization process, which involves introducing the synthesized compound analogues to the special NR2F6 protein molecule and cellular systems.

Regen BioPharma, Inc. Announces the Company Canceled 31.5 Million Shares

Management has agreed to cancel 16,500,000 common shares and 15,000,000 Series A Preferred shares. Of these amounts, 7,500,000 common shares and 2,500,000 Series A Preferred shares were already cancelled in December 2016 with the remaining shares being submitted for cancellation on March 13, 2017. The shares were considered compensation for management.

Previous Items of Significance

HemaXellerate's approval and clearance by the FDA to commence Human Trials with the New Drug. That resulted in two things. One RGBP transitioned from a R&D company, morphing into a Clinical Trials Company, a major step in the progress of the company and credibility. Second RGBP attracted their first viable partner as the (NIH) agency NCATS agreed to collaborate with clinical trials using HemaXellerate for a treatment of the rare blood disease/disorder aPlastic Anemia.

New Partners - NIH (NCATS) - Pan Am Cancer Research and Treatment Center - Eli Lily & Company -

Weill Cornell Medical College (Cornell University)

HemaXellerate II was discovered to be effective in treating an additional market much more vast than aPlastic Anemia. It is in the early stage of development to treat Bone Marrow Suppression, a common disorder due to Chemotherapy. This finding occurred at/with another new partner The Pan Am Cancer Research and Treatment Center where ongoing Trials are being conducted.

Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

dCell Vax (Treatment for Breast Cancer) seems to be at last news in the final comments with the FDA to gain approval to commence Human Trials with Breast Cancer Patients.

The NIH (NCATS) also is collaborating with Regen and working together to screen small molecule compounds that activate or inhibit orphan nuclear receptor, NR2F6 (Research Project), cell lines will be provided by Regen. Regen also has a partnership with Eli Lily working together with NR2F6.

For all the news-Details on other treatments HemaXellerate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, uCell Vax, Car-T Cell for various Cancers, Autoimmune, Rare Blood Disorders/Diseases, Leukemia, etc. Open the link below.

We believe Regen BioPharma is a Long Play, with a great upside with all the items in its Pipeline. Very possibly a Buy Out Target-They do already have some impressive Partners, today that list Grew.

RGBP also has Short Term Gain Potential that has been proven time and again since we began following them. Increases-Bounces in Share Pricing ranging from 30%-400% and more at various intervals.

Research this Diamond in the Rough. Profit more than likely awaits at this entry level. Recently RGBP Bounced from $.04 up to $.096-Backed off on Profits gained to $.05 and is up 15.45% to $.065 today with over One Million Shares. (1.2 million plus shares at 10:40 am)

Robert E. Kreh

Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

(OTCBB:RGBP) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at www.otcmarkets.com. Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to robkreh@smallcapsolutions.com or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile(s) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.

Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com and/or otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(s)/Broker Dealer(s) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to robkreh@smallcapsolutions.comor by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.